June 20, 2021
Business News

FDA approves first personalized cell therapy for multiple myeloma – STAT

The Food and Drug Administration on Friday approved the first personalized cell therapy to treat patients with advanced multiple myeloma. It will be marketed under the brand name Abecma by its makers, Bristol Myers Squibb and Bluebird Bio.
Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell that helps fight infections. In people with multiple myeloma, malignant plasma cells accumulate in the bone marrow, where they crowd out healthy blood cells, causing tumors, kidney…

Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Tablet Prime Day Deals (2021): Early Apple iPad, Samsung Galaxy Tablet, Fire HD & Kindle Savings Monitored by Retail Egg
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Arcimoto, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
AON Splash Image
Air Fryer Prime Day Deals 2021: Early Cuisinart, Ninja, Instant, Philips & More Sales Identified by Saver Trends